Literature DB >> 11888284

Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications.

Virna Dapić1, Paula J Bates, John O Trent, Alison Rodger, Shelia D Thomas, Donald M Miller.   

Abstract

Oligonucleotide-based therapies have considerable potential in cancer, viral, and cardiovascular disease therapies. However, it is becoming clear that the biological effects of oligonucleotides are not solely due to the intended sequence-specific interactions with nucleic acids. Oligonucleotides are also capable of interacting with numerous cellular proteins owing to their polyanionic character or specific secondary structure. We have examined the antiproliferative activity, protein binding, and G-quartet formation of a series of guanosine-rich oligonucleotides, which are analogues of GRO29A, a G-quartet forming, growth-inhibitory oligonucleotide, whose effects we have previously described [Bates P. J., Kahlon, J. B., Thomas, S. D., Trent, J. O., and Miller, D. M. (1999) J. Biol. Chem. 274, 26369-26377]. The GRO29A analogues include phosphorothioate (PS29A), 2'-O-methyl RNA (MR29A), and mixed DNA/2'-O-methyl RNA (MRdG29A) oligonucleotides. We demonstrate by UV spectroscopy that all of the modified analogues form stable structures, which are consistent with G-quartet formation. We find that the phosphorothioate and mixed DNA/2'-O-methyl analogues are able to significantly inhibit proliferation in a number of tumor cell lines, while the 2'-O-methyl RNA has no significant effects. Similar to the original oligonucleotide, GRO29A, the growth inhibitory oligonucleotides were able to compete with the human telomere sequence oligonucleotide for binding to a specific cellular protein. The less active MR29A does not compete significantly for this protein. On the basis of molecular modeling of the oligonucleotide structures, it is likely that the inactivity of MR29A is due to the differences in the groove structure of the quadruplex formed by this oligonucleotide. Interestingly, all GRO29A analogues, including an unmodified DNA phosphodiester oligonucleotide, are remarkably resistant to nuclease degradation in the presence of serum-containing medium, indicating that secondary structure plays an important role in biological stability. The remarkable stability and strong antiproliferative activity of these oligonucleotides confirm their potential as therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11888284     DOI: 10.1021/bi0119520

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  42 in total

1.  Resolution of quadruplex polymorphism by size-exclusion chromatography.

Authors:  M Clarke Miller; John O Trent
Journal:  Curr Protoc Nucleic Acid Chem       Date:  2011-06

2.  Nucleolin interacts with the dengue virus capsid protein and plays a role in formation of infectious virus particles.

Authors:  Corey A Balinsky; Hana Schmeisser; Sundar Ganesan; Kavita Singh; Theodore C Pierson; Kathryn C Zoon
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

Review 3.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

Review 4.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

5.  Aptamer photoregulation in vivo.

Authors:  Lele Li; Rong Tong; Hunghao Chu; Weiping Wang; Robert Langer; Daniel S Kohane
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

6.  Quick chip assay using locked nucleic acid modified epithelial cell adhesion molecule and nucleolin aptamers for the capture of circulating tumor cells.

Authors:  Nihal G Maremanda; Kislay Roy; Rupinder K Kanwar; Vidyarani Shyamsundar; Vijayalakshmi Ramshankar; Arvind Krishnamurthy; Subramanian Krishnakumar; Jagat R Kanwar
Journal:  Biomicrofluidics       Date:  2015-09-29       Impact factor: 2.800

7.  Resolution and characterization of the structural polymorphism of a single quadruplex-forming sequence.

Authors:  Magdalena M Dailey; M Clarke Miller; Paula J Bates; Andrew N Lane; John O Trent
Journal:  Nucleic Acids Res       Date:  2010-03-25       Impact factor: 16.971

8.  Effect of locked-nucleic acid on a biologically active g-quadruplex. A structure-activity relationship of the thrombin aptamer.

Authors:  Laura Bonifacio; Frank C Church; Michael B Jarstfer
Journal:  Int J Mol Sci       Date:  2008-03-24       Impact factor: 6.208

9.  Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics.

Authors:  John S Vorhies; John J Nemunaitis
Journal:  Biologics       Date:  2007-12

10.  Cancer-selective antiproliferative activity is a general property of some G-rich oligodeoxynucleotides.

Authors:  Enid W Choi; Lalitha V Nayak; Paula J Bates
Journal:  Nucleic Acids Res       Date:  2009-12-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.